Lumexa Imaging (LMRI) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Lumexa Imaging (NASDAQ: LMRI):

• 9/28/2026 – Lumexa Imaging was given a new $17.00 price target by Raymond James Financial, Inc..
• 9/28/2026 – Lumexa Imaging had its “strong-buy” rating reaffirmed by UBS Group AG.
• 9/24/2026 – Lumexa Imaging is now covered by KeyCorp. They set an “overweight” rating and a $18.00 price target on the stock.
• 9/24/2026 – Lumexa Imaging is now covered by KeyCorp. They set an “overweight” rating and a $18.00 price target on the stock.
• 9/22/2026 – Lumexa Imaging had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 9/12/2026 – Lumexa Imaging was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/28/2026 – Lumexa Imaging had its price target raised by Barclays PLC from $9.00 to $13.00. They now have an “overweight” rating on the stock.
• 8/16/2026 – Lumexa Imaging was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/13/2026 – Lumexa Imaging was given a new $16.00 price target by Deutsche Bank Aktiengesellschaft.
• 8/8/2026 – Lumexa Imaging was downgraded by Wall Street Zen from “buy” to “hold”.

Lumexa Imaging, Inc (NASDAQ: LMRI) is an outpatient diagnostic imaging company that provides medical imaging services to patients and referring healthcare providers in the United States. Its services are designed to support the diagnosis, monitoring and management of a wide range of medical conditions.

The company’s imaging capabilities include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET/CT), ultrasound, mammography and X-ray services. Lumexa also provides related radiology and imaging-support services through its outpatient centers and other care-delivery arrangements.

Lumexa Imaging was formerly known as Akumin Inc and adopted the Lumexa Imaging name as part of its corporate rebranding.